Roswell Park Comprehensive Cancer Center
Survivin may be target for immunotherapies in several malignancies
VIDEO: Cancer vaccine targets glioblastoma
Studies offer new insights into treatment of children, adolescents with Hodgkin lymphoma
Pembrolizumab plus CMP-001 demonstrates efficacy for anti-PD-1 resistant melanoma

The combination of pembrolizumab and CMP-001, an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with metastatic melanoma resistant to PD-1 checkpoint inhibition, according to study results presented at American Association for Cancer Research Annual Meeting.
Neoadjuvant nivolumab induces pathologic responses in advanced resectable non-small cell lung cancer
Immunotherapy-chemotherapy combination extends survival in newly diagnosed metastatic lung cancer

CHICAGO — The addition of the anti-PD-1 therapy pembrolizumab to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who do not harbor EGFR or ALK alterations, according to results of the randomized phase 3 KEYNOTE-189 trial presented at American Association for Cancer Research Annual Meeting.